TOP ONCOLOGY CRO
EXPERTS IN CLINICAL ONCOLOGY
QUALITY ONCOLOGY TRIAL MONITORING
home blog news careers français contact
QUALITY ONCOLOGY TRIAL MANAGEMENT



The Reverse Feasibility Program™

A Novel CRO Approach to Site Selection
& Patient Recruitment

Reverse Feasibility Program for 50% faster site start-up.A revolutionary approach to feasibility assessment that accelerates study start-up by matching your protocol with the current study needs of motivated and pre-qualified North American sites.

How it works...


Oncology Clinical Trial News

Scimega launches Canadian expansion of an ongoing Phase 1 / 2 Study of an HSP90 Inhibitor Alone and in Combination with Crizotinib in the Treatment of Non-small Cell Lung Cancer.

Scimega launches Canadian expansion of an ongoing Phase 1b, open-label study to assess the safety and tolerability of an orally active, reversible and selective HER2 inhibitor combined with trastuzumab emtansine (TDM1) in HER2+metastatic breast cancer..

Scimega launches Canadian Phase II exploratory study to identify biomarkers predictive of clinical response to an oral multi-kinase inhibitor in patients with metastatic colorectal cancer who have failed first-line therapy.

See all news...

Upcoming Scimega Events

American Society of Hematology (ASH) 56th Annual Meeting

Dec. 6-8, 2014 in San Francisco

Clinical Operations in Oncology Trials – West Coast

April 17-18, 2015 in Burlingame, CA

AACR Annual Meeting (American Association for Cancer Research)

April 18-22, 2015 in Philadelphia

See all upcoming events...


Latest Podcast

Centralized Ethics Review for Oncology Trials in Canada

An interview with Janet Manzo, Executive Director, Ontario Cancer Research Ethics Board
Listen...



Copyright © Scimega Research Inc. 2014. All rights reserved.
Privacy Policy

Oncology CRO   Clinical Trial Monitoring   Clinical Trial Management   Oncology Community